In 2019, the combination of pembrolizumab with platinum and fluorouracil was also approved for patients with metastatic, unresectable, or recurrent tumours, regardless of PD-L1 expression, as well as the administration of pembrolizumab alone in patients with a combined positive score (CPS) ≥ 1 regarding PD-L1 expression [14]. This evidence concerns the gene CD274 and neoplasm.